Physician profile
Daniel Levi Willis
NPI 1023211547
$2,658.16
in general payments reported to CMS, 2019-2025
26 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.31 · 2021: $26.39 · 2022: $138 · 2023: $541 · 2024: $983 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Travel and Lodging: $435 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.90 |
| Travel and Lodging | $434.97 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $453.14 | 2025 | |
| Boston Scientific Corporation | $262.47 | 2021-2025 | Ams 700 |
| Abbvie INC. | $225.80 | 2024-2025 | |
| Medtronic, INC. | $214.06 | 2024 | V-Loc 180, Ligasure |
| Sumitomo Pharma America, INC. | $192.76 | 2023-2025 | Gemtesa, Orgovyx |
| W. L. Gore & Associates, INC. | $175.00 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Conmed Corporation | $140.60 | 2024 | Airseal |
| Dornier Medtech America, INC | $126.00 | 2024 | Dornier Medtech |
| Bayer Healthcare Pharmaceuticals INC. | $99.88 | 2023-2025 | |
| Accord Healthcare, INC. | $90.32 | 2024-2025 | |
| Bk Medical Holding Company INC. | $73.00 | 2023 | Bk3000, Bk3500 & Bk5000 Ultrasound System |
| Ferring Pharmaceuticals INC. | $70.70 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $70.15 | 2022-2025 | Jelmyto |
| Astellas Pharma US INC | $55.00 | 2019 | |
| Agiliti Surgical, INC. | $53.95 | 2023 | Dornier Thulio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.71 | 2024-2025 | Imfinzi, Lynparza |
| Tolmar, INC. | $45.75 | 2024-2025 | Eligard, Jatenzo |
| Janssen Biotech, INC. | $43.17 | 2024 | Erleada |
| Olympus America INC. | $40.00 | 2025 | Itind System |
| Intuitive Surgical, INC. | $36.66 | 2024 | |
| Myriad Genetic Laboratories, INC. | $35.46 | 2022 | |
| Progenics Pharmaceuticals, INC. | $28.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.80 | 2025 | |
| Calyxo, INC. | $20.23 | 2025 | Cvac Aspiration System |
| Coloplast Corp | $16.82 | 2022 | |
| Travere Therapeutics, INC. | $12.77 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.